Fortress Biotech

Update in progress

FBIO (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Fortress Biotech, Inc. is a biopharmaceutical company focused on developing and commercializing medicines across dermatology, oncology, infectious disease, and related areas. Its portfolio includes Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, Luxamend, Tramadol, CUTX-101, UNLOXCYT, Olafertinib, CAEL-101, Triplex, and early-stage programs such as Dotinurad, MB-101, MB-108, MB-109, MB-106, AJ201, BAER-101, plus preclinical gene therapies and other platforms. Formerly Coronado Biosciences; renamed in 2015. Based in Bay Harbor Islands, Florida, since 2006.

Company score

Sentiment: -0.12; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.03; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.06; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive